AUPH
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- LUPKYNIS was associated with a statistically significant 53% reduction in risk of renal-related events or deathJun 4, 2026
- Aurinia announces positive results from Phase 1 study of Aritinercept (AUR200)Jun 30, 2025
- New AURORA 1 data shows LUPKYNIS-based triple immunosuppressive therapy significantly reduces proteinuria in lupus nephritisMay 22, 2025